Your browser doesn't support javascript.
loading
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019.
Danpanichkul, Pojsakorn; Suparan, Kanokphong; Dutta, Priyata; Kaeosri, Chuthathip; Sukphutanan, Banthoon; Pang, Yanfang; Kulthamrongsri, Narathorn; Jaisa-Aad, Methasit; Ng, Cheng Han; Teng, Margaret; Nakano, Masahito; Morishita, Asahiro; Alkhouri, Naim; Yang, Ju Dong; Chen, Vincent L; Kim, Donghee; Fallon, Michael B; Diaz, Luis Antonio; Arab, Juan Pablo; Mantzoros, Christos S; Noureddin, Mazen; Lazarus, Jeffrey V; Wijarnpreecha, Karn.
Afiliación
  • Danpanichkul P; Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. Electronic address: pojsakorndan@gmail.com.
  • Suparan K; Immunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Dutta P; Department of Internal Medicine, Trinity Health, Ann Arbor, MI, USA.
  • Kaeosri C; Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Sukphutanan B; Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Pang Y; Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi 533000, China; National Immunological Laboratory of Traditional Chinese Medicine, Baise, Guangxi 533000, China; Key Laboratory of Research on Clinical Molecular Diagnosis for High Incidence Diseases in Western Guang
  • Kulthamrongsri N; Department of Internal Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, Hawaii, USA.
  • Jaisa-Aad M; Department of Neurology, West Virginia University, Morgantown, WV, USA.
  • Ng CH; Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Teng M; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
  • Nakano M; Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Morishita A; Department of Gastroenterology and Neurology, Kagawa University, Kita-gun, Kagawa 761-0793, Japan.
  • Alkhouri N; Department of Hepatology, Arizona Liver Health, Chandler, AZ, USA.
  • Yang JD; Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Chen VL; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Kim D; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
  • Fallon MB; Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA; Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ, USA.
  • Diaz LA; Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile; Observatorio Multicéntrico de Enfermedades Gastrointestinales, OMEGA, Santiago, Chile; MASLD Research Center, Division of Gastroenterology and Hepatology, University of California San D
  • Arab JP; Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile; Observatorio Multicéntrico de Enfermedades Gastrointestinales, OMEGA, Santiago, Chile; Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia
  • Mantzoros CS; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Medicine, Boston VA Healthcare System, Boston, MA, USA.
  • Noureddin M; Houston Research Institute and Houston Methodist Hospital, Houston, TX, USA.
  • Lazarus JV; The Global NASH Council, Washington, DC, USA; CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Ba
  • Wijarnpreecha K; Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA; Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ, USA; BIO5 Institute, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.
Metabolism ; 158: 155958, 2024 Jun 26.
Article en En | MEDLINE | ID: mdl-38942169
ABSTRACT

OBJECTIVE:

Metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic conditions affect populations across economic strata. Nevertheless, there are limited epidemiological studies addressing these diseases in low (LICs) and lower-middle-income countries (lower MICs). Therefore, an analysis of the trend of MASLD and cardiometabolic conditions in these countries is necessary.

METHODS:

From 2000 to 2019, jointpoint regression analysis was employed to calculate the prevalence, mortality, and disability-adjusted life years (DALYs) for cardiometabolic conditions including MASLD, type 2 diabetes mellitus (T2DM), dyslipidemia (DLP), hypertension (HTN), obesity, peripheral artery disease (PAD), atrial fibrillation and flutter (AF/AFL), ischemic heart disease (IHD), stroke, and chronic kidney disease from HTN and T2DM, in LICs and lower MICs (according to the World Bank Classification 2019) using the Global Burden of Disease 2019 data.

RESULTS:

Among the eleven cardiometabolic conditions, MASLD (533.65 million), T2DM (162.96 million), and IHD (76.81 million) had the highest prevalence in LICs and Lower MICs in 2019. MASLD represented the largest proportion of global prevalence in these countries (43 %). From 2000 to 2019, mortality in LICs and lower MICs increased in all cardiometabolic conditions, with obesity-related mortality having the highest increase (+134 %). During this timeframe, there were increased age-standardized death rates (ASDR) from obesity, PAD, and AF/AFL. From all conditions, the DALYs-to-prevalence ratio was higher in LICs and lower MICs than the global average.

CONCLUSION:

The burden of MASLD and cardiometabolic conditions is increasing worldwide, with LICs and lower MICs experiencing higher (DALYs) disability per prevalence. As these conditions are preventable, counteracting these trends requires not only the modification of ongoing actions but also the strategizing of immediate interventions.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Metabolism Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Metabolism Año: 2024 Tipo del documento: Article